证券代码：688276 证券简称：百克生物 公告编号：2025-022 长春百克生物科技股份公司 关于自愿披露重组带状疱疹疫苗（CHO 细胞） 临床试验申请获得批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、长春百克生物科技股份公司（以下简称"公司"）近日收到国家药品监督 管理局下发的重组带状疱疹疫苗（CHO 细胞）的《药物临床试验批准通知书》。 二、重组带状疱疹疫苗（CHO 细胞）的简介 带状疱疹是由潜伏在机体内的水痘-带状疱疹病毒（VZV）重新被激活引起的 急性感染性皮肤病，该病毒具有嗜神经性，初次感染后可长期潜伏在脊髓神经后根 或脑神经节的神经元内，在某些诱因的刺激下，潜伏的病毒沿感觉神经移动到达支 配的皮肤，迅速增殖复制使受感染细胞发炎、坏死造成神经痛，并沿着神经纤维通 路到达皮肤表面，出现呈带状分布的红斑及簇集水疱。带状疱疹多发于老年人和免 2、本次获批临床试验的重组带状疱疹疫苗（CHO 细胞）后续临床试验的开展 具有一定的不确定性，能否最终实现商业目的也存在一定的不确定性。敬请广 ...

证券代码：688276 证券简称：百克生物 公告编号：2025-021 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，长春百克生物科技股份公司（以下简称 "公司"）将参加由吉林省证券业协会、深圳市全景网络有限公司共同举办的 "2025 年吉林辖区上市公司投资者网上集体接待日活动"，现将有关事项公告如 下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP， 参与本次互动交流。活动时间为 2025 年 5 月 27 日（周二）15:00-16:30。 届时公司董事、总经理姜春来先生、独立董事吴安平先生、财务总监孟昭峰 先生、董事会秘书张喆先生将在线就公司 2024 年度业绩、公司治理、发展战略、 经营状况等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃 参与！ 特此公告。 长春百克生物科技股份公司董事会 2025 年 5 月 20 日 长春百克生物科技股份公司 关于 ...

Core Viewpoint - The price reduction trend for self-paid vaccines has reached the shingles vaccine, with significant price cuts observed in various regions of China, aiming to increase vaccination rates among the population [1][2]. Price Reduction and Promotional Activities - Since March 2023, the price of shingles vaccines in regions like Inner Mongolia, Shandong, Henan, and Chongqing has been halved compared to last year, with some areas offering "buy one get one free" promotions [2]. - The "2025 Domestic Shingles Vaccine Benefit Project" offers a half-price vaccination for residents over 40, reducing the original price from 1389 yuan to 704.5 yuan, saving 684.5 yuan [3]. - A promotional activity allows individuals to complete the first dose between May and August 2025 and the second dose by December 31, 2025, reducing the total cost from 3260 yuan to 1652 yuan [4][6]. Market Competition and Pricing Discrepancies - The two available shingles vaccines in China, one imported from GlaxoSmithKline and one domestic from Baike Biological, are experiencing inconsistent price reductions, leading to regional competition [7]. - In some areas, only the imported vaccine has seen a price drop, while the domestic vaccine remains at its original price [7]. Vaccination Rates and Challenges - The vaccination rate for shingles among adults aged 40 and older in China is extremely low, at only 0.79% as of September 2024, compared to 41.1% in the U.S. for those aged 60 and above [12][13]. - High self-paid prices are a significant barrier to increasing vaccination rates, with the cost of the imported vaccine previously equating to nearly a month's pension for retirees in cities like Guangzhou [14]. - There is a lack of awareness and understanding of shingles and its vaccine among the elderly, further limiting vaccination uptake [12][15]. Inventory and Sales Performance - Baike Biological has faced challenges with unsold inventory, leading to a significant increase in accounts receivable and inventory levels, indicating poor sales performance [8][9]. - GlaxoSmithKline's vaccine has seen a decline in expected sales, with procurement agreements being extended to 2029 due to underperformance [10][11]. Healthcare Infrastructure and Service Limitations - The current healthcare infrastructure for adult vaccination is inadequate, with insufficient resources and a lack of clear guidelines for adult immunization services [16]. - Many vaccination centers are not equipped to handle adult vaccinations, leading to a conservative approach in recommending vaccines to the elderly [16].

Group 1 - The legal opinion letter confirms the legality of the convening and holding procedures of Changchun Baike Biotechnology Co., Ltd.'s 2024 annual shareholders' meeting [1][2][4] - The meeting was convened by the company's sixth board of directors and held on May 13, 2025, with a combination of on-site and online voting [3][4] - A total of 96 shareholders (or their proxies) attended the meeting, representing 290,916,681 shares, which is 70.3278% of the total voting shares [4][5] Group 2 - The voting results for the agenda items were as follows: - For the 2024 Board of Directors Work Report, 99.8660% voted in favor [5] - For the 2024 Supervisory Board Work Report, 99.8660% voted in favor [6] - For the 2024 Profit Distribution Plan, 99.9287% voted in favor [6] - For the 2024 Annual Report, 99.8340% voted in favor [7] - For the Director Compensation Plan, 99.3688% voted in favor, with related shareholders abstaining [8] - For the Supervisor Compensation Plan, 99.6008% voted in favor, with related shareholders abstaining [9] - For the appointment of the 2025 financial audit and internal control audit institutions, 99.8390% voted in favor [10] Group 3 - The legal opinion concludes that the convening, holding procedures, qualifications of the convenor and attendees, as well as the voting procedures and results of the meeting are all in compliance with relevant laws, regulations, and the company's articles of association [2][10]

证券代码：688276 证券简称：百克生物 公告编号：2025-020 长春百克生物科技股份公司 2024年年度股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 96 | | --- | --- | | 普通股股东人数 | 96 | | 2、出席会议的股东所持有的表决权数量 | 290,916,681 | | 普通股股东所持有表决权数量 | 290,916,681 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 70.3278 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 70.3278 | （四）表决方式是否符合《公司法》及公司章程的规定，会议主持情况等。 （一）股东会召开的时间：2025 年 5 月 13 日 （二）股东会召开的地点：长春百克生物科技股份公司 5 楼会议室（吉林省长春 市卓越大街 138 号） （三）出席会议的普通股股东 ...

北京植德律师事务所 关于长春百克生物科技股份公司 2024 年年度股东会的 法律意见书 植德京（会）字[2025]0048号 二〇二五年五月 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编：100007 12th Floor, Raffles City Beijing Offices Tower, No.1 Dongzhimen South Street,Dongcheng District, Beijing 100007 P.R.C. 电话（Tel）: 010-56500900 传真（Fax）: 010-56500999 www.meritsandtree.com 北京植德律师事务所 关于长春百克生物科技股份公司 2024 年年度股东会的 法律意见书 植德京（会）字[2025]0048 号 致：长春百克生物科技股份公司（贵公司） 北京植德律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席 并见证贵公司 2024 年年度股东会（以下简称"本次会议"）。 2．本所律师无法对网络投票过程进行见证，参与本次会议网络投票的股东资格、 1 网络投票结果均由上海证券交易所交易系统和互联网投票系 ...

- The report predicts adjustments to the sample stocks of seven major broad-based indices in the Chinese market, including CSI 300, CSI 500, SSE 50, STAR 50, STAR 100, ChiNext Index, and ChiNext 50, based on the index compilation rules and data as of April 30, 2025 [1][7] - The CSI 300 Index selects stocks from the Shanghai and Shenzhen markets that meet criteria such as good operational status, no significant financial issues, and no abnormal price fluctuations. The selection process involves ranking stocks by daily average trading volume and market capitalization over the past year, applying buffer rules, and excluding stocks with significant losses or long-term suspensions. Adjustments are limited to 10% of the constituent stocks per review [8] - The CSI 500 Index excludes CSI 300 constituents and follows a similar methodology, focusing on stocks with good operational status, no financial irregularities, and stable price movements. Stocks are ranked by daily average trading volume and market capitalization, with buffer rules applied, and adjustments are capped at 10% of the constituent stocks [10] - The SSE 50 Index is derived from the SSE 180 Index, selecting stocks based on daily average market capitalization and trading volume over the past year. The accuracy of SSE 50 predictions depends on the SSE 180 Index's accuracy. Adjustments are limited to 10% of the constituent stocks [13] - The STAR 50 Index represents the top 50 securities on the STAR Market by market capitalization and liquidity. Stocks are ranked by daily average market capitalization, with buffer rules applied, and adjustments are capped at 10% of the constituent stocks [15] - The STAR 100 Index includes 100 mid-sized securities from the STAR Market, reflecting the performance of mid-cap companies. The selection process is similar to STAR 50, with adjustments limited to 10% of the constituent stocks [17] - The ChiNext Index selects stocks from the ChiNext Board based on the top-ranked daily average market capitalization over the past six months. Buffer rules are applied, and stocks with significant losses or long-term suspensions are excluded. Adjustments are capped at 10% of the constituent stocks [20] - The ChiNext 50 Index selects the most liquid stocks from the ChiNext Index's 100 constituents, considering industry coverage and applying buffer rules. Adjustments are limited to 10% of the constituent stocks [24]

Investment Rating - The report does not explicitly state an investment rating for the vaccine industry Core Insights - The overall trend in the vaccine industry shows a decline in batch approvals for most vaccine types in Q1 2025, with some exceptions showing recovery or growth in demand [7][29][46] Summary by Category Multi-Component Vaccines - In Q1 2025, multi-component vaccines saw a total of 17 batch approvals, a decrease of 26% compared to the previous year [11][15] - The five-component vaccine maintained its batch approval at 17, while the four-component vaccine had no approvals [15][12] Pneumonia Vaccines - Total batch approvals for pneumonia vaccines in Q1 2025 were 23, down 30% year-on-year [19][21] - The 13-valent pneumonia vaccine had 19 approvals, remaining stable, while the 23-valent vaccine saw a significant drop to 4 approvals, down 71% [24][19] HPV Vaccines - HPV vaccine approvals increased to 57 batches in Q1 2025, a growth of 63% [29][27] - The two-valent HPV vaccine saw a remarkable increase of 367%, with all approvals coming from Wantai Biological Pharmacy [29][32] Influenza Vaccines - Influenza vaccine approvals totaled 29 batches, a significant increase of 263% year-on-year [34][38] - The three-valent influenza vaccine had 28 approvals, while the four-valent vaccine had only 1 approval, down 67% [38][41] Rabies Vaccines - Batch approvals for rabies vaccines increased to 223 in Q1 2025, a growth of 37% [46][48] - The freeze-dried rabies vaccine accounted for the majority of approvals, with Chengda Biological achieving 105 approvals, a 110% increase [48][46] Varicella Vaccines - Varicella vaccine approvals slightly decreased to 83 batches, down 2% [53][54] - The largest contributor was Baike Biological, with 33 approvals, marking a 38% increase [54][53] Hib Vaccines - Hib vaccine approvals fell to 7 batches, a decrease of 50% [59][58] EV71 Vaccines - EV71 vaccine approvals continued to decline, with only 4 batches approved, down 69% [64][63] Rotavirus Vaccines - Rotavirus vaccine approvals totaled 21 batches, a decrease of 46% [68][67] DTP Vaccines - DTP vaccine approvals increased to 18 batches, a growth of 167% [72][73] Meningitis Vaccines - Meningitis vaccine approvals totaled 85 batches, down 34% [78][79] - The AC polysaccharide vaccine accounted for 55 approvals, a decrease of 47% [84][79] Hepatitis B Vaccines - Hepatitis B vaccine approvals increased to 87 batches, a growth of 28% [91][90] IPV Vaccines - IPV vaccine approvals totaled 22 batches, a decrease of 33% [93][92]

Core Viewpoint - The financial report of Changchun High-tech shows a significant decline in both revenue and net profit, marking the end of an 18-year growth trend, leading to a sharp drop in stock price [2][4][24]. Group 1: Financial Performance - In 2024, the company's operating revenue was 13.47 billion yuan, a decrease of 7.55% compared to 2023, which was 14.57 billion yuan [3]. - The net profit attributable to shareholders was 2.58 billion yuan, down 43.01% from 4.53 billion yuan in 2023 [3]. - Basic earnings per share fell to 6.42 yuan, a decline of 42.73% from 11.21 yuan in the previous year [3]. - The total assets at the end of 2024 were 31.05 billion yuan, a slight increase of 1% from 30.74 billion yuan in 2023 [3]. Group 2: Market Dynamics - The decline in performance is attributed to the impact of centralized procurement policies, which led to significant price reductions for key products, particularly the long-acting growth hormone [12][14]. - The revenue from Jin Sai Pharmaceutical, a subsidiary, was 10.67 billion yuan, down 3.73%, with net profit dropping 40.67% to 2.68 billion yuan [12]. - The competitive landscape has intensified, with new entrants offering lower-priced alternatives, threatening Changchun High-tech's market position [19]. Group 3: Cost and Investment - The company faced increased costs, with R&D expenses rising by 25.75% to 2.17 billion yuan, driven by accelerated new product development [13]. - Sales expenses increased by 11.81% to 4.44 billion yuan due to a rise in sales personnel to cope with market competition [13]. - Management expenses also grew by 25.59% to 1.20 billion yuan, further squeezing profit margins [13]. Group 4: Future Outlook - Despite the current downturn, the company is focusing on innovation and international expansion, with 24 key products in clinical stages [20]. - The approval of new products, such as the recombinant follicle-stimulating hormone injection, is expected to contribute over 500 million yuan in revenue by 2025 [20]. - However, uncertainties remain regarding the sustainability of growth and the impact of ongoing competitive pressures and market conditions [24].

Core Insights - The market for shingles vaccines in China has experienced rapid growth due to an aging population and increased public health awareness, with the market size expected to reach 5.6 billion yuan by 2024 after a recovery from a significant drop in 2021 [1][13] - The incidence of shingles is notably high among individuals aged 50 and above, driving sustained demand for vaccines [1][13] - The public's awareness of shingles and its prevention is gradually increasing, further propelling the market's growth [1][13] Industry Overview - Shingles vaccines are designed to prevent shingles, a disease caused by the reactivation of the Varicella-Zoster Virus, which initially causes chickenpox [2][4] - The industry chain includes upstream raw material suppliers, midstream vaccine developers and manufacturers, and downstream logistics and healthcare providers [4] Development History - The shingles vaccine industry in China has evolved from non-existence to local innovation, with the first imported vaccine, GSK's Shingrix, approved in 2019 [6][9] - The launch of the first domestic live attenuated shingles vaccine by Baike Biological in January 2023 marked a significant milestone, expanding the eligible age group for vaccination [6][9] - The market is now characterized by competition between imported and domestic vaccines, with expectations for a surge in domestic vaccine approvals in the coming years [6][9] Market Dynamics - The number of vaccine approvals has increased significantly, with Baike Biological's vaccine receiving 22 approvals in the first three quarters of 2023, indicating strong market performance [9] - The domestic vaccine market is expected to grow rapidly, driven by aging demographics and improved public health policies [9][11] Key Companies - Baike Biological has established itself as a leader in the shingles vaccine market, with a revenue of 883 million yuan in 2023, although it is projected to decline to 251 million yuan in 2024 [17] - Wantai Biological, another key player, reported a revenue of 5.511 billion yuan in 2023, down 50.73% from the previous year, and is expected to generate 2.245 billion yuan in 2024 [19] Future Trends - Domestic vaccines are anticipated to dominate the market due to their competitive pricing and alignment with local needs [21] - The improvement of health insurance policies is expected to enhance vaccine accessibility and increase public willingness to get vaccinated [22] - The development of multivalent and combination vaccines is becoming a significant trend, aiming to provide broader protection and improve vaccination efficiency [23]